49 results on '"Elion, Richard A."'
Search Results
2. Changes in weight and BMI with first-line doravirine-based therapy
3. Characteristics Associated with Response to Antiretroviral Therapy (ART) among People Living with Human Immunodeficiency Virus (PLWH)
4. LB-7. Weight Change in Suppressed People with HIV (PWH) Switched from Either Tenofovir Disoproxil Fumarate (TDF) or Abacavir (ABC) to Tenofovir Alafenamide (TAF)
5. 1704. Regional and Racial Disparities in Response to Antiretroviral Therapy (ART) among People Living with Human Immunodeficiency Virus (PLWH)
6. Quarterly screening optimizes detection of sexually transmitted infections when prescribing HIV preexposure prophylaxis
7. Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCV
8. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial
9. 2553. Addressing Knowledge and Practice Gaps in HIV Management with Engaging Continuing Education
10. Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate
11. Brief Report: Short-Term Adherence Marker to PrEP Predicts Future Nonretention in a Large PrEP Demo Project: Implications for Point-of-Care Adherence Testing
12. Estimated Impact of Targeted Pre-Exposure Prophylaxis: Strategies for Men Who Have Sex with Men in the United States
13. 1320. Continuing Education Improves HIV Screening and Use of PrEP in High-Risk Patients
14. 550. Adherence and Persistency With Modern Single vs. Multi-Tablet Antiretroviral (ARV) Regimens in First Treatment of HIV in Clinical Practice
15. Patterns and Correlates of Participant Retention in a Multi-City Pre-Exposure Prophylaxis Demonstration Project
16. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial
17. Changes in Kidney Function Associated With Daily Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Preexposure Prophylaxis Use in the United States Demonstration Project
18. Hair levels of preexposure prophylaxis drugs measure adherence and are associated with renal decline among men/transwomen
19. Increased Risk of Myocardial Infarction in HIV-Infected Individuals in North America Compared With the General Population
20. Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial
21. Disparities in achieving and sustaining viral suppression among a large cohort of HIV-infected persons in care – Washington, DC*
22. Efficacy and Safety of Tenofovir Alafenamide versus Tenofovir Disoproxil Fumarate in HIV-infected, Virologically Suppressed Black and Non-Blacks Adults Through Week 48: Subgroup Analysis of a Randomized Switch Study
23. Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and Community-Based Sexual Health Services
24. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study
25. The preexposure prophylaxis revolution
26. Authors' Reply
27. Sorting Through the Lost and Found
28. High Interest in Preexposure Prophylaxis Among Men Who Have Sex With Men at Risk for HIV Infection
29. Ombitasvir, Paritaprevir Co-dosed With Ritonavir, Dasabuvir, and Ribavirin for Hepatitis C in Patients Co-infected With HIV-1
30. Safety and efficacy of ombitasvir - 450/r and dasabuvir and ribavirin in HCV/HIV-1 co-infected patients receiving atazanavir or raltegravir ART regimens
31. Tenofovir Alafenamide Vs. Tenofovir Disoproxil Fumarate in Single Tablet Regimens for Initial HIV-1 Therapy
32. Rilpivirine Versus Efavirenz with Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naïve HIV-1–Infected Patients with HIV-1 RNA ≤100,000 Copies/mL: Week 96 Pooled ECHO/THRIVE Subanalysis
33. 1223Ledipasvir/Sofosbuvir is Safe and Effective as a Single-Tablet-Regimen for Treatment of Patients with Genotype 1 Chronic Hepatitis C Virus, Including those with Compensated Cirrhosis
34. A Randomized Phase 3 Study Comparing Once-Daily Elvitegravir With Twice-Daily Raltegravir in Treatment-Experienced Subjects With HIV-1 infection
35. Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection
36. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection
37. Inflammatory biomarkers and abacavir use in the Women's Interagency HIV Study and the Multicenter AIDS Cohort Study
38. The Prevalence of Rectal, Urethral, and Pharyngeal Neisseria gonorrheae and Chlamydia trachomatis among Asymptomatic Men Who Have Sex with Men in a Prospective Cohort in Washington, D.C.
39. Modulation of K65R Selection by Zidovudine Inclusion: Analysis of HIV Resistance Selection in Subjects with Virologic Failure Receiving Once-Daily Abacavir/Lamivudine/Zidovudine and Tenofovir DF (Study COL40263)
40. HIV Policy: The Path Forward—A Joint Position Paper of the HIV Medicine Association of the Infectious Diseases Society of America and the American College of Physicians
41. W1817 Entecavir (ETV) Therapy in Chronic Hepatitis B Patients Previously Treated with Adefovir (ADV) with Incomplete Response On-Treatment or Relapse Off-Treatment
42. Antiviral Activity, Pharmacokinetics, and Dose Response of the HIV-1 Integrase Inhibitor GS-9137 (JTK-303) in Treatment-Naive and Treatment-Experienced Patients
43. Once-daily antiretroviral therapies for HIV infection: Consensus statement of an Advisory Committee of the International Association of Physicians in AIDS Care
44. The safety profile and antiviral activity of the combination of stavudine, didanosine, and nelfinavir in patients with HIV infection
45. Weight Loss as a Predictor of Survival and Disease Progression in HIV Infection
46. COMPLEMENTARY MEDICINE AND HIV INFECTION
47. The Physician-Patient Relationship in AIDS Management
48. Antibody testing and ambulatory care
49. The insomnia of ?sleeping in a strange place?: Effects of l-tryptophane
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.